Get the Stockscreener App
4.9559
2.07%
-0.1141
Organogenesis Holdings Inc stock is traded at $4.9559, with a volume of 430.70K.
It is down -2.07% in the last 24 hours and up +46.89% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$5.07
Open:
$4.97
24h Volume:
430.70K
Relative Volume:
0.28
Market Cap:
$643.02M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
138.82
EPS:
0.0357
Net Cash Flow:
$6.55M
1W Performance:
-5.43%
1M Performance:
+46.89%
6M Performance:
+75.44%
1Y Performance:
+77.32%
1-Day Range:
$4.915
$5.115
1-Week Range:
$4.8609
$5.40
52-Week Range:
$2.165
$6.71
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
4.955 | 643.02M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
163.29 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.12 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.35 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.34 | 18.62B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.53 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis Holdings: Solid Finances Protect From Uncertain Environment (NASDAQ:ORGO) - Seeking Alpha
Organogenesis (NASDAQ:ORGO) Stock Price Down 2.1% – What’s Next? - Defense World
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Rhumbline Advisers Acquires 7,621 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) - Defense World
Morgan Stanley Increases Organogenesis (NASDAQ:ORGO) Price Target to $6.00 - Defense World
Organogenesis director Michael Driscoll sells $127,535 in stock By Investing.com - Investing.com South Africa
Organogenesis director Michael Driscoll sells $127,535 in stock - Investing.com India
High Growth Stocks Insiders Are Eager To Own - Simply Wall St
Organogenesis (NASDAQ:ORGO) Trading 9.1% Higher on Analyst Upgrade - Defense World
Organogenesis Holdings Reports Strong Q4 Earnings Amid Challenges - TipRanks
Best Growth Stocks To Watch Now – March 1st - Defense World
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ORGO, MARA and OSH - ACCESS Newswire
Best Small Cap Stocks To Follow NowMarch 2nd - MarketBeat
Small Cap Stocks To Keep An Eye OnMarch 1st - MarketBeat
Best Growth Stocks To Watch NowMarch 1st - MarketBeat
There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise - Simply Wall St
Organogenesis (NASDAQ:ORGO) Sets New 52-Week High – Here’s What Happened - Defense World
Promising Growth Stocks To ConsiderFebruary 28th - MarketBeat
ORGO stock touches 52-week high at $4.64 amid market fluctuations By Investing.com - Investing.com South Africa
CGI Inc. (GIB) Stock Forecasts - Yahoo Finance
Organogenesis (NASDAQ:ORGO) Issues Earnings Results - MarketBeat
United States shares higher at close of trade; Dow Jones Industrial Average up 1.39% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.39% - Investing.com
ORGO stock touches 52-week high at $4.64 amid market fluctuations - Investing.com
Today’s top stories: pain management innovation and revenue jumps - RagingBull
Cantor Fitzgerald lifts Organogenesis price target to $6.00 By Investing.com - Investing.com Canada
Cantor Fitzgerald lifts Organogenesis price target to $6.00 - Investing.com
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Earnings call transcript: Organogenesis Q4 2024 sees earnings beat, stock surges - Investing.com India
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Organogenesis stock surges on earnings beat, strong guidance By Investing.com - Investing.com South Africa
U.S. Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2025-2032: AbbVie Inc., Johnson - EIN News
Organogenesis: Q4 Earnings Snapshot - mySA
After-Market Rally: Organogenesis (ORGO) Stock Spikes On Earnings Beat - Stocks Telegraph
Organogenesis (ORGO) Q4 2024 Earnings Call Transcript - AOL
Organogenesis (ORGO) Q4 2024 Earnings Call Transcript - The Motley Fool
Organogenesis Holdings Reports Strong Q4 2024 Results - TipRanks
Organogenesis stock surges on earnings beat, strong guidance - Investing.com India
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Organogenesis Q4 2024 sees earnings beat, stock surges By Investing.com - Investing.com South Africa
Organogenesis stock jumps 17% on Q4 report, outlook - MSN
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results - The Manila Times
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times
Can Organogenesis Maintain Momentum After Q4 Revenue Jumps 27% and Profit Rebounds? - StockTitan
U.S. Tissue Engineering Market Size to Hit USD 69.00 Billion by 203 - BioSpace
Starbucks is getting rid of these 13 drinks in March. Here's what to know - Yahoo
Organogenesis Holdings Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Advancements In Bioink Technology For Tissue Engineering : Key Trend Transformation in the Cell Regeneratio... - WhaTech
Asia Pacific Wound Care Biologics Market Generated - openPR
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Organogenesis Holdings Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022ORGO - ACCESS Newswire
Organogenesis (ORGO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 04 '25 |
Sale |
5.10 |
25,000 |
127,535 |
166,879 |
| Gillheeney Gary S. | President and CEO |
Dec 13 '24 |
Sale |
3.36 |
55,615 |
186,866 |
3,044,779 |
| Gillheeney Gary S. | President and CEO |
Dec 16 '24 |
Sale |
3.49 |
5,585 |
19,492 |
3,039,194 |
| Gillheeney Gary S. | President and CEO |
Dec 11 '24 |
Sale |
3.64 |
157,448 |
573,111 |
3,143,753 |
| Gillheeney Gary S. | President and CEO |
Dec 10 '24 |
Sale |
3.64 |
58,525 |
213,031 |
3,301,201 |
| Gillheeney Gary S. | President and CEO |
Dec 12 '24 |
Sale |
3.55 |
43,359 |
153,924 |
3,100,394 |
| Gillheeney Gary S. | President and CEO |
Dec 05 '24 |
Option Exercise |
0.99 |
1,067,245 |
1,056,573 |
3,419,194 |
| Gillheeney Gary S. | President and CEO |
Dec 09 '24 |
Sale |
3.52 |
41,052 |
144,503 |
3,359,726 |
| Gillheeney Gary S. | President and CEO |
Dec 06 '24 |
Sale |
3.65 |
18,416 |
67,218 |
3,400,778 |
0.69%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):